ATAI Life Sciences B.V.*(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ATAI ATAI Life Sciences B.V.*

休市中 08-29 16:00:00 EDT

4.58

-0.07

-1.51%

盘后4.50

-0.08-1.75%

19:53 EDT

最高4.73	最低4.40	成交量309.11万
今开4.65	昨收4.65	日振幅7.10%
总市值9.82亿	流通市值5.54亿	总股本2.14亿
成交额1,408万	换手率2.55%	流通股本1.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ATAI","market":"US","secType":"STK","nameCN":"ATAI Life Sciences B.V.*","latestPrice":4.58,"timestamp":1756497600000,"preClose":4.65,"halted":0,"volume":3091080,"hourTrading":{"tag":"盘后","latestPrice":4.5,"preClose":4.58,"latestTime":"19:53 EDT","volume":18495,"amount":84352.1915,"timestamp":1756511637785},"delay":0,"floatShares":121000000,"shares":214338329,"eps":-0.905668,"marketStatus":"休市中","change":-0.07,"latestTime":"08-29 16:00:00 EDT","open":4.65,"high":4.73,"low":4.4,"amount":14080844.635739999,"amplitude":0.070968,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.905668,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1756800000000},"marketStatusCode":7,"adr":1,"adrRate":2,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":4.65,"dividendRate":0.000218,"preHourTrading":{"tag":"盘前","latestPrice":4.6418,"preClose":4.65,"latestTime":"09:26 EDT","volume":17411,"amount":80853.04510100001,"timestamp":1756474013366},"postHourTrading":{"tag":"盘后","latestPrice":4.5,"preClose":4.58,"latestTime":"19:53 EDT","volume":18495,"amount":84352.1915,"timestamp":1756511637785},"volumeRatio":0.381868,"impliedVol":1.335,"impliedVolPercentile":0.544},"requestUrl":"/m/hq/s/ATAI","defaultTab":"news","newsList":[{"id":"2559951300","title":"ATAI Life Sciences Q2 EPS $(0.14) Misses $(0.12) Estimate, Sales $719.000K Up From $273.000K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2559951300","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559951300?lang=zh_cn&edition=full","pubTime":"2025-08-14 19:17","pubTimestamp":1755170222,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 61.11 percent increase over losses of $(0.36) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"ATAI Life Sciences第二季度EPS$(0.14)低于$(0.12)预期，销售额从去年同期的273,000 K美元增至719,000 K美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47117724/atai-life-sciences-q2-eps-0-14-misses-0-12-estimate-sales-719-000k-up-from-273-000k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI"],"gpt_icon":0},{"id":"2559590949","title":"Earnings Flash (ATAI) Atai Life Sciences Posts Q2 Net Loss $0.14 a Share, vs. FactSet Est of $0.11 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2559590949","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559590949?lang=zh_cn&edition=full","pubTime":"2025-08-14 19:07","pubTimestamp":1755169655,"startTime":"0","endTime":"0","summary":"Earnings Flash (ATAI) Atai Life Sciences Posts Q2 Net Loss $0.14 a Share, vs. FactSet Est of $0.11 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"财报(ATAI)Atai Life Sciences公布第二季度每股净亏损0.14美元，而FactSet预计亏损0.11美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATAI"],"gpt_icon":0},{"id":"2554798357","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2554798357","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554798357?lang=zh_cn&edition=full","pubTime":"2025-07-28 19:46","pubTimestamp":1753703211,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences  shares were 10% lower pre-bell Monday after saying Friday that its phase 2b trial of inidascamine in patients with cognitive impairment associated with schizophrenia failed to achieve its primary endpoint.Kazia Therapeutics  stock was down 10% following a 1.4% loss in the previous session.Linkhome Holdings  shares were 9.3% lower, paring Friday's 83% rally.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"盘前跌幅最大的股票","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","KZIA","ATAI","BK4139"],"gpt_icon":0},{"id":"2536261263","title":"Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2536261263","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536261263?lang=zh_cn&edition=full","pubTime":"2025-05-20 20:04","pubTimestamp":1747742679,"startTime":"0","endTime":"0","summary":"Atai Life Sciences  said Tuesday that topline data from a phase 2a trial showed that a single dose of its drug BPL-003, when given to patients who were also taking defined selective serotonin reuptake inhibitors, produced antidepressive effects of up to three months.The drug was well-tolerated with no serious adverse events, and an average in-clinic treatment time following dosing of less than two hours, the company said.The 12-patient study showed average MADRS score reductions of 18 to 19 points up to three months post-treatment, supporting prior monotherapy findings, Atai said.Atai shares were 3.8% lower in recent premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Atai Life Sciences报告难治性抑郁症药物2a期结果积极","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATAI","BK4007","BK4539"],"gpt_icon":0},{"id":"2535026033","title":"ATAI Life Sciences Q1 EPS $(0.15) Beats $(0.18) Estimate, Sales $1.55M","url":"https://stock-news.laohu8.com/highlight/detail?id=2535026033","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535026033?lang=zh_cn&edition=full","pubTime":"2025-05-14 20:21","pubTimestamp":1747225260,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 11.76 percent increase over losses of $(0.17) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"ATAI Life Sciences第一季度EPS$(0.15)超出预期$(0.18)，销售额155万美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45404379/atai-life-sciences-q1-eps-0-15-beats-0-18-estimate-sales-1-55m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI"],"gpt_icon":0},{"id":"2520752222","title":"ATAI Life Sciences(ATAI.US)：2024年Q4财报实现营收-5000美元，前值为1.8万美元，预期值为25万美元；每股收益为-0.24美元，前值为-0.12美元，预期值为-0.15美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2520752222","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2520752222?lang=zh_cn&edition=full","pubTime":"2025-03-17 21:43","pubTimestamp":1742219005,"startTime":"0","endTime":"0","summary":"ATAI Life Sciences(ATAI.US)：2024年Q4财报实现营收-5000美元，前值为1.8万美元，预期值为25万美元；每股收益为-0.24美元，前值为-0.12美元，预期值为-0.15美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/17214348807750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ATAI"],"gpt_icon":0},{"id":"1180765533","title":"ATAI生命科学公司第四季度每股收益$(0.24)未达预期$(0.15)","url":"https://stock-news.laohu8.com/highlight/detail?id=1180765533","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180765533?lang=zh_cn&edition=full","pubTime":"2025-03-17 20:08","pubTimestamp":1742213317,"startTime":"0","endTime":"0","summary":"ATAI生命科学公司报告季度每股亏损为$，未达到分析师预测的$，低于预期60％。与去年同期每股亏损$相比，下降了100％。以上内容来自Benzinga Earnings专栏，原文如下：ATAI Life Sciences  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 60 percent. This is a 100 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ATAI生命科学公司第四季度每股收益$(0.24)未达预期$(0.15)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATAI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atai.life","stockEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.3199},{"period":"3month","weight":0.9827},{"period":"6month","weight":1.6628},{"period":"1year","weight":2.5231},{"period":"ytd","weight":2.4436}],"compareEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":0.0167},{"period":"3month","weight":0.0944},{"period":"6month","weight":0.0856},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ATAI Life Sciences N.V.于2020年9月10日根据荷兰法律注册为Adripa Holding B.V.。2021年1月11日，更名为ATAI Life Sciences B.V.。他们是一家临床阶段的生物制药公司，旨在改变精神疾病的治疗方法。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.051111},{"month":2,"riseRate":0.75,"avgChangeRate":0.055077},{"month":3,"riseRate":0.5,"avgChangeRate":-0.057424},{"month":4,"riseRate":0.75,"avgChangeRate":0.001524},{"month":5,"riseRate":0.25,"avgChangeRate":0.04946},{"month":6,"riseRate":0,"avgChangeRate":-0.082337},{"month":7,"riseRate":0.8,"avgChangeRate":0.230191},{"month":8,"riseRate":0.6,"avgChangeRate":-0.017917},{"month":9,"riseRate":0,"avgChangeRate":-0.156517},{"month":10,"riseRate":0,"avgChangeRate":-0.063751},{"month":11,"riseRate":0.5,"avgChangeRate":0.118488},{"month":12,"riseRate":0.25,"avgChangeRate":-0.11215}],"exchange":"NASDAQ","name":"ATAI Life Sciences B.V.*","nameEN":"ATAI Life Sciences B.V.*"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATAI Life Sciences B.V.*(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ATAI Life Sciences B.V.*(ATAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ATAI Life Sciences B.V.*,ATAI,ATAI Life Sciences B.V.*股票,ATAI Life Sciences B.V.*股票老虎,ATAI Life Sciences B.V.*股票老虎国际,ATAI Life Sciences B.V.*行情,ATAI Life Sciences B.V.*股票行情,ATAI Life Sciences B.V.*股价,ATAI Life Sciences B.V.*股市,ATAI Life Sciences B.V.*股票价格,ATAI Life Sciences B.V.*股票交易,ATAI Life Sciences B.V.*股票购买,ATAI Life Sciences B.V.*股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATAI Life Sciences B.V.*(ATAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ATAI Life Sciences B.V.*(ATAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况